FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022362404> ?p ?o ?g. }

• W2022362404 endingPage "220" @default.
• W2022362404 startingPage "213" @default.
• W2022362404 abstract "Abstract Twenty previously synthesized fused heterocyclic DNA‐topoisomerase II (Topo II)‐inhibiting compounds were investigated for their potential efficacy in various human cancer cell lines that were derived from different tumor entities. Moreover, different multidrug‐resistant variants of these cancer cell lines with decreased Topo II expression were investigated. In parental, drug‐sensitive cells merely the compounds BD3 and G35 showed efficacies, in terms of μM, which were similar to that of the classical Topo II inhibitor etoposide. On the other hand, most of the tested heterocyclic compounds were found more effective in drug‐resistant cells than in the parental, drug‐sensitive ones, and some of the compounds showed high antineoplastic efficacy in several drug‐resistant cell models. Compounds BD13, BD14 and BD16 exhibited high antineoplastic activities against the drug‐resistant sublines EPG85‐257RNOV and EPG85‐257RDB derived from gastric carcinoma, EPP85‐181RNOV and EPP85‐181RDB derived from pancreatic carcinoma, MCF‐7/Adr derived from breast cancer, D79/86RNOV derived from fibrosarcoma, and MeWoETO1 derived from melanoma. Furthermore, compound D23 was found highly efficient in the multidrug‐resistant variants HT‐29RNOV and HT‐29RDB derived from colon carcinoma, and compound D24 exhibited the highest antineoplastic activity among the tested compounds in the drug‐resistant subline MDA‐MB‐231ROV derived from breast cancer. In conclusion, compounds BD 13, BD 14, BD 16, D 23 and D 24 may be useful for the treatment of different multidrug‐resistant cancer cells with cross resistance against “classical” Topo II‐targeting drugs. © 2006 Wiley‐Liss, Inc." @default.
• W2022362404 created "2016-06-24" @default.
• W2022362404 creator A5024499062 @default.
• W2022362404 creator A5066337566 @default.
• W2022362404 creator A5084048612 @default.
• W2022362404 date "2006-04-17" @default.
• W2022362404 modified "2023-10-16" @default.
• W2022362404 title "High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs" @default.
• W2022362404 cites W1547338899 @default.
• W2022362404 cites W1555798239 @default.
• W2022362404 cites W162187343 @default.
• W2022362404 cites W1849296542 @default.
• W2022362404 cites W1973179542 @default.
• W2022362404 cites W1979498399 @default.
• W2022362404 cites W1986241682 @default.
• W2022362404 cites W1994127646 @default.
• W2022362404 cites W1999078067 @default.
• W2022362404 cites W2003962564 @default.
• W2022362404 cites W2010511880 @default.
• W2022362404 cites W2025495816 @default.
• W2022362404 cites W2025944270 @default.
• W2022362404 cites W2031676888 @default.
• W2022362404 cites W2040054070 @default.
• W2022362404 cites W2042367294 @default.
• W2022362404 cites W2046494390 @default.
• W2022362404 cites W2046792018 @default.
• W2022362404 cites W2047046246 @default.
• W2022362404 cites W2051982697 @default.
• W2022362404 cites W2069019428 @default.
• W2022362404 cites W2087055737 @default.
• W2022362404 cites W2089799526 @default.
• W2022362404 cites W2091032640 @default.
• W2022362404 cites W2111047350 @default.
• W2022362404 cites W2173418622 @default.
• W2022362404 cites W2255395527 @default.
• W2022362404 cites W293630621 @default.
• W2022362404 cites W2950383642 @default.
• W2022362404 cites W4254595987 @default.
• W2022362404 doi "https://doi.org/10.1002/ijc.21792" @default.
• W2022362404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16450374" @default.
• W2022362404 hasPublicationYear "2006" @default.
• W2022362404 type Work @default.
• W2022362404 sameAs 2022362404 @default.
• W2022362404 citedByCount "46" @default.
• W2022362404 countsByYear W20223624042012 @default.
• W2022362404 countsByYear W20223624042013 @default.
• W2022362404 countsByYear W20223624042014 @default.
• W2022362404 countsByYear W20223624042015 @default.
• W2022362404 countsByYear W20223624042016 @default.
• W2022362404 countsByYear W20223624042017 @default.
• W2022362404 countsByYear W20223624042018 @default.
• W2022362404 countsByYear W20223624042019 @default.
• W2022362404 countsByYear W20223624042020 @default.
• W2022362404 countsByYear W20223624042021 @default.
• W2022362404 countsByYear W20223624042022 @default.
• W2022362404 countsByYear W20223624042023 @default.
• W2022362404 crossrefType "journal-article" @default.
• W2022362404 hasAuthorship W2022362404A5024499062 @default.
• W2022362404 hasAuthorship W2022362404A5066337566 @default.
• W2022362404 hasAuthorship W2022362404A5084048612 @default.
• W2022362404 hasBestOaLocation W20223624041 @default.
• W2022362404 hasConcept C114851261 @default.
• W2022362404 hasConcept C121608353 @default.
• W2022362404 hasConcept C133936738 @default.
• W2022362404 hasConcept C147897179 @default.
• W2022362404 hasConcept C185592680 @default.
• W2022362404 hasConcept C2776694085 @default.
• W2022362404 hasConcept C2778119113 @default.
• W2022362404 hasConcept C2778616834 @default.
• W2022362404 hasConcept C2780035454 @default.
• W2022362404 hasConcept C2780500152 @default.
• W2022362404 hasConcept C502942594 @default.
• W2022362404 hasConcept C54355233 @default.
• W2022362404 hasConcept C552990157 @default.
• W2022362404 hasConcept C55493867 @default.
• W2022362404 hasConcept C81885089 @default.
• W2022362404 hasConcept C86803240 @default.
• W2022362404 hasConcept C96232424 @default.
• W2022362404 hasConcept C98274493 @default.
• W2022362404 hasConceptScore W2022362404C114851261 @default.
• W2022362404 hasConceptScore W2022362404C121608353 @default.
• W2022362404 hasConceptScore W2022362404C133936738 @default.
• W2022362404 hasConceptScore W2022362404C147897179 @default.
• W2022362404 hasConceptScore W2022362404C185592680 @default.
• W2022362404 hasConceptScore W2022362404C2776694085 @default.
• W2022362404 hasConceptScore W2022362404C2778119113 @default.
• W2022362404 hasConceptScore W2022362404C2778616834 @default.
• W2022362404 hasConceptScore W2022362404C2780035454 @default.
• W2022362404 hasConceptScore W2022362404C2780500152 @default.
• W2022362404 hasConceptScore W2022362404C502942594 @default.
• W2022362404 hasConceptScore W2022362404C54355233 @default.
• W2022362404 hasConceptScore W2022362404C552990157 @default.
• W2022362404 hasConceptScore W2022362404C55493867 @default.
• W2022362404 hasConceptScore W2022362404C81885089 @default.
• W2022362404 hasConceptScore W2022362404C86803240 @default.
• W2022362404 hasConceptScore W2022362404C96232424 @default.
• W2022362404 hasConceptScore W2022362404C98274493 @default.
• W2022362404 hasIssue "1" @default.

• next